Guido Neels joins Endologix board of directors
This article was originally published in Clinica
Irvine, California-based aortic treatment firm Endologix has added Guido Neels to its board of directors. Mr Neels is currently managing director at Essex Woodlands Health Ventures, a majority shareholder of Nellix – an endograft specialist acquired by Endologix earlier this year (www.clinica.co.uk, 28 October 2010). Mr Neels also holds board positions at oxygen saturation firm ROX Medical, endoscopic sinus surgery company Entellus Medical, stereotactic specialist Oraya Therapeutics, biomaterials expert Arsenal Medical and cryopreservation business EndGenitor Technologies. He was previously chief operating officer of Guidant, which was bought by Boston Scientific in 2006. The Endologix board now consists of five independent directors and three non-independent directors.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals